Akèy › Emoglobinopati
Etid klinik pou Emoglobinopati ap rekrite nan Etazini
14 etid pou Emoglobinopati ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- St. Louis, MO4 etid
- New York City, NY4 etid
- Philadelphia, PA3 etid
- Nashville, TN3 etid
- Minneapolis, MN3 etid
- Memphis, TN3 etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling
Ap rekriteFaz 1 bonè
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT06313398Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
Ap rekriteFaz 1/2
Jiska laj 20 · Tout sèks · Mizajou Sep 16, 2026 · NCT00920972Long Term Follow-Up Study for Individuals With Hemoglobin Disorders After Hematopoietic Cell Transplant or Gene Therapy
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Sep 15, 2026 · NCT06646640The HOPE Biobank Resource (BMT CTN 2402 HOPE)
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Aug 27, 2026 · NCT07227155Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
Ap rekrite
Jiska laj 55 · Tout sèks · Mizajou Jul 6, 2026 · NCT01666080TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
Ap rekriteFaz 2
Laj 0 a 21 · Tout sèks · Mizajou Jul 1, 2026 · NCT04356469Allo HSCT for High Risk Hemoglobinopathies
Ap rekriteFaz 2Volontè an sante akeyi
Jiska laj 55 · Tout sèks · Mizajou Jun 4, 2026 · NCT06872333Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Ap rekriteFaz 1/2
1 Day – 21 Years · Tout sèks · Mizajou May 29, 2026 · NCT03128996Discarded Bone Marrow for Hematology Research
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 5, 2026 · NCT04671212Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Ap rekriteFaz 1/2
1 Month – 25 Years · Tout sèks · Mizajou Apr 15, 2026 · NCT06839456Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Ap rekriteFaz 3
Laj 12 a 35 · Tout sèks · Mizajou Mar 23, 2026 · NCT05477563Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Ap rekriteFaz 2
Jiska laj 21 · Tout sèks · Mizajou Mar 13, 2026 · NCT04644016A Long-term Follow-up Study in Patients Who Received BEAM-101
Ap rekriteEtid obsèvasyon
Laj 14 a 37 · Tout sèks · Mizajou Jan 28, 2026 · NCT07373639Study of the Role of Genetic Modifiers in Hemoglobinopathies
Ap rekriteEtid obsèvasyon
Laj 2 ak plis · Tout sèks · Mizajou Mar 20, 2024 · NCT05799118Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.